License-out
<From LTT to other companies>

As a drug discovery-related bio-venture, we aim to License out our pipelines under development to other companies as early as possible. Some of them have already proceeded to phase II clinical trials. The followings are brief explanations about our pipelines under development. Please contact us, if you would like us to send you reference materials or you would like to meet us to get more information.

(1) PC-SOD as a therapeutic agent for renal diseases, cerebral infarction, myocardial infarction, and ARDS

As explained in the other section, PC-SOD, which can remove reactive oxygen species, an underlying cause of many diseases effectively, is promising as a therapeutic agent for various diseases.
In terms of idiopathic pulmonary fibrosis and ulcerative colitis, our phase II clinical trial actually indicates the efficacy of PC-SOD. In China, we are currently conducting the phase II clinical trial of PC-SOD in patients with myocardial infarction. The efficacy was demonstrated in animal models with a wide variety of diseases, such as COPD, dry mouth, myocardial infarction, spinal code injury, heat injury, traumatic brain damage, and disability at transplant, as well as these diseases, stroke, scleroderma, or ARDS. We can license our substance patent and use patent in terms of all of these diseases.
And we are also pleased to work with you in collaborative development. Focusing on renal disorders, cerebral infarction, myocardial infarction, ARDS, and diseases whose names are not disclosed (for protection of intellectual property of the drugs), we are preparing for the clinical trials of the drugs. In particular, we hope to license the patents for the drugs or to collaborate with partners in the development of drugs related to the treatment of these diseases.

【Target drug】LT-1001 (iv), LT-1002 (inhalation)(PC-SOD)
【Target diseases】Renal disorders, cerebral infarction, myocardial infarction, ARDS, ulcerative colitis, idiopathic pulmonary fibrosis, and other diseases
【Development stage】Phase I clinical trials being completed; phase II clinical trials for some of the target diseases being completed
【IP】Substance patent, use patents, formulation patents

(2) Stealth-type polymeric nanoparticles, a DDS carrier characterized by accumulation and sustained-release

Unlike previous DDS carriers characterized by either accumulation or sustained-release, we successfully developed the first stealth-type polymeric nanoparticles with both of these functions in the world. The following (3) and (4) describe examples of development with this technology. We also possess the patent for the particle itself and can offer collaborative development and research by encapsulating a drug you want to into the particle.

(3) Nano-PGE1 as a therapeutic agent for chronic artery occlusive disease

Having contributed to treatment for many patients, our lipo-PGE1 has a problem of QOL because it requires daily injections. Therefore, we developed nano-PGE1 that encapsulates PGE1 in a DDS carrier, stealth-type polymeric nanoparticles characterized by accumulation and sustained release. This product is expected to have higher effects by administration about every two weeks than that by daily administration of lipo-PGE1.

【Target drug】LT-2002 (Nano-PGE1)
【Target disease】Peripheral artery occlusive disease
【Development stage】In nonclinical trials
【IP】Formulation patent

(4) NanoPGI2 derivative as a therapeutic agent for pulmonary hypertension

Currently, for treatment of pulmonary hypertension, continuous PGI2 infusion via pump or oral administration of a PGI2 derivative are mainly used; however, the former and latter have problems of QOL and effect, respectively. Therefore, we developed the nano-BPS that encapsulates PGI2 derivative(BPS) in a DDS carrier, stealth-type polymeric nanoparticles characterized by accumulation, and sustained release. This product accumulates on the affected vascular site and releases PGI2 derivative, and it is expected to have sufficient effect by administration even every two weeks.

【Target drug】LT-2004 (Nano-PGI2 derivative)
【Target disease】Pulmonary arterial hypertension
【Development stage】In nonclinical trials
【IP】Formulation patent

(5) New NSAIDs with less gastric ulcer and excellent in fast-acting

Nonsteroidal anti-inflammatory drugs (NSAIDs) are clinically essential as antipyretic analgesics, but NSAID-related gastric ulcers have become a big problem. A new NSAID we discovered (LT-3001) is much less likely to develop gastric ulcers and has a more fast-acting effect compared to existing NSAIDs. We hope to license the patent for the substance in a nonclinical trial and the subsequent phases.

【Target drug】LT-3001 (New chemical)
【target disease】Inflammatory diseases
【Development stage】In nonclinical trials
【IP】Substance patent

(6) Therapeutic agent for COPD with long-acting bronchodilatory and anti-inflammatory effects

In the current treatment of patients with COPD, a long-acting bronchodilator for improvement of symptoms and steroid therapy for delay of disease progression are mainly used. LT-3002, which we discovered, has a longer bronchodilatory effect than existing bronchodilators and a stronger anti-inflammatory effect than steroids in animal experiments. We hope to license the patent for this promising new substance as a therapeutic agent for COPD in a nonclinical trial and the subsequent phases.

【Target drug】LT-3002 (New chemical)
【target disease】COPD
【Development stage】In nonclinical trials
【IP】Substance patent

(7) Therapeutic agent for COPD with bronchodilatory and anti-inflammatory effects (approved drug)

In the current treatment of patients with COPD, a long-acting bronchodilator for improvement of symptoms and steroid therapy for delayed disease progression are mainly used. We discovered LT-4001, an approved drug with bronchodilatory and anti-inflammatory effects from our approved drug library and hope to license the patent for this substance along with LT-3002 mentioned in the above (6).

【Target drug】LT-4001 (Approved drug)
【target disease】COPD
【Development stage】As the drugs are already approved, nonclinical trials and the phase I clinical trial have been completed.
【IP】Use patents, formulation patent

(8) Therapeutic agent for dry eye that works based on a new mechanism

Treatment for dry eye has not been established yet regardless of the launch and development of pharmaceutical drugs that work on various mechanisms. We focused attention on the fact that there is currently no drug to protect the cornea against injury from hyperosmolar tears and discovered the approved drug LT-4002, using our approved-drug library. The early phase II clinical trial has recently been completed and indicated the safety and efficacy of the drug. The later phase II clinical trial is currently ongoing.

【Target drug】LT-4002 (Approved drug)
【target disease】Dry eye
【Development stage】In the late phase II clinical trial
【IP】Use patents, Formulation patent

(9) Approved drug to enhance the efficacy of anticancer drugs

In treatment with anticancer drugs, a reduction of the effective concentration of anticancer drugs by a concomitant drug leads to improvement of the pharmaceutical effect and reduction of adverse reactions. With regard to anticancer drug A, it has been clinically considered that the use of this drug, which is effective in the treatment of certain types of refractory cancers, should be restricted because it causes serious gastrointestinal disorders. As a result of the screening of approved drugs using our library jointly with the University of Shizuoka, we discovered LT-4009, an approved drug that can enhance the anticancer effect of anticancer drug A.

【Target drug】LT-4009 (Approved drug)
【target disease】Cancer
【Development stage】As an approved drug, nonclinical trials and the phase I clinical trial have been completed.
【IP】Use patents, formulation patent

(10) New mechanism-based drug for treatment of pulmonary fibrosis

Idiopathic pulmonary fibrosis is a disease characterized by pulmonary fibrosis of the lungs and decreased respiratory functions over time. The five-year survival rate is less than 40%, and the prognosis for the disease is said to be worse than that of lung cancer. This disease is thought to be caused by activation of myofibroblasts. As a result of the screening of approved drugs using our library jointly with Musashino University, we discovered LT-4010, an approved drug that can reduce the activation of myofibroblasts.

【Target drug】LT-4010 (Approved drug)
【target disease】Pulmonary fibrosis
【Development stage】As the drugs are already approved, nonclinical trials and the phase I clinical trial have been completed.
【IP】Use patents

(11) Therapeutic agent for neurodegenerative diseases through autophagy induction

Autophagy is a major mechanism of degradation of the cytosolic component with lysosome. Recent research has shown that autophagy selectively degrades the coagulable abnormal proteins that may cause neurodegenerative diseases (for example, Alzheimer's disease or polyglutamine disease) and prevent the accumulation and coagulation of the proteins. So, a drug that activates autophagy is expected to be a radical therapeutic agent for neurodegenerative diseases. Actually, results from many recent studies have supported this hypothesis. We worked collaboratively with Noboru Mizushima, professor at the University of Tokyo, who is an authority on autophagy research in mammals to search for pharmaceutical drugs that inhibit autophagy, and finally discovered LT-4007, multiple approved drugs.

【Target drug】LT-5001 (Approved drug)
【target disease】Not disclosed
【Development stage】In the late phase II clinical trial
【IP】Not disclosed

Inquiry about collaborative development